Luteinizing hormone-releasing hormone antagonist cetrorelix as primary single therapy in patients with advanced prostatic cancer and paraplegia due to metastatic invasion of spinal cord

Author: Gonzalez-Barcena D.   Vadillo-Buenfil M.   Cortez-Morales A.   Fuentes-Garcia M.   Cardenas-Cornejo I.   Comaru-Schally A.M.   Schally A.V.  

Publisher: Elsevier

ISSN: 0090-4295

Source: Urology, Vol.45, Iss.2, 1995-02, pp. : 275-281

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content